eli lilly oral tirzepatide F.D.A. Approves New Obesity Drug That Will Compete With Wegovy Lilly's oral GLP-1 Foundayo (orforglipron)

Find out more about Ro's Body Program

A Certificate of Analysis is a laboratory document containing analytical information specific to an individual production batch where available

With the emergence of GLP-1s, there is a divide between patient perception of the medication and how clinical science views it

A new class of medicines is reshaping how we think about obesity, diabetes, and chronic disease

The data supports continued use in: Type 2 diabetes Obesity and metabolic syndrome Patients with cardiometabolic risk factors Reasonable caution is still appropriate in individuals with: Active pancreatitis Recurrent idiopathic pancreatitis Severe hypertriglyceridemia until corrected